

Page 1

1                   IN THE UNITED STATES DISTRICT COURT  
2                   FOR THE NORTHERN DISTRICT OF OHIO  
3                   EASTERN DIVISION  
4  
5     IN RE: NATIONAL PRESCRIPTION                       )  
6                   OPIATE LITIGATION                       )  
7    ) MDL No. 2804  
8     THIS DOCUMENT RELATES TO:                       ) Case No. 17-md-2804  
9    )  
10                  Track Eight: Cobb County, Georgia   )  
11                  Case No. 1:18-op-45817                   )  
12                  COBB COUNTY,                              )  
13                  Plaintiff,                                )  
14                  vs.                                        )  
15                  PURDUE PHARMA, L.P., et al.,           )  
16                  Defendants.                              )  
17  
18  
19  
20  
21  
22  
23  
24  
25

VIDEOTAPED DEPOSITION OF  
CARMEN CATIZONE, MS, RPh, DPh  
Chicago, Illinois  
Thursday, May 30th, 2024

REPORTED BY: GREG S. WEILAND, CSR, RMR, CRR  
JOB NO.: 6693118

1                   THE WITNESS: Both.

2 BY MS. WHITE:

3 Q. Both, okay.

4 A. And if I can explain.

5 Q. Sure.

6 A. The 14 red flags in Dr. McCann's report  
7 was the directions to a person who analyzes data.

8                   The presentation in my report where some  
9 of those red flags were linked under a particular  
10 heading is how, as an expert, and how the practice  
11 of pharmacy and how a pharmacist would encounter  
12 those red flags within those headings.

13                  And so that presentation would be  
14 different than the directions I would give to  
15 someone analyzing the data that would have no idea  
16 what I'm talking about or what the data would be.

17                  And so there is a difference in how  
18 they're presented, but they both refer to the same  
19 things, and those red flags have always been a part  
20 of pharmacy practice.

21 Q. Do you remember last week when Albertson's  
22 counsel asked you about the 25-mile rule, for  
23 example?

24 A. I remember her asking, but go ahead.

25 Q. And my memory is that you said the

1           That would be the same for the  
2           pharmacists.

3 BY MS. WHITE:

4           Q. Where would an independent pharmacist go  
5 to look for a list of red flags that would be  
6 applicable in Georgia?

7           A. Same places that a corporate and chain  
8 pharmacist would go to: The federal law, state law,  
9 guidance provided by the DEA, guidance provided by  
10 the State Board of Pharmacy, and then information,  
11 their trade association, if they're a member of the  
12 National Community Pharmacists Association would  
13 provide to members as well.

14           Q. Is that NCPA?

15           A. Yes, it is.

16           Q. Okay. Now going back to 2006.

17           In 2006, could an independent pharmacist  
18 in Georgia, looking for guidance on red flags, have  
19 found that list of 14 red flags written down  
20 anywhere?

21           A. The list written, as this is, no.

22           Q. Today could an independent pharmacist in  
23 Georgia, looking for guidance on red flags, find  
24 that list of 14 red flags written down anywhere?

25           A. Yes.

1 the flag exists.

2 Q. That's not my question.

3 Does the flag exist when it's presented,  
4 if the pharmacist knows it's less than 25 miles?

5 MR. ELSNER: Objection.

6 THE WITNESS: I wouldn't be a red flag if  
7 it was less than 25 miles.

8 BY MS. WHITE:

9 Q. Okay. My understanding of your prior  
10 testimony would mean that you do not have an opinion  
11 on how many of the 16,700 prescriptions were  
12 actually for an illegitimate purpose; is that fair?

13 A. Correct.

14 Q. My understanding of your prior testimony  
15 is that you do not know how many of those 16,700  
16 prescriptions the pharmacist performed due diligence  
17 on but didn't write it down?

18 MR. ELSNER: Objection.

19 THE WITNESS: I would say based upon my  
20 report, 95 percent or more of those  
21 prescriptions were not resolved.

22 BY MS. WHITE:

23 Q. That's not my question, sir.

24 My question is, you don't know how many  
25 that pharmacist did due diligence on, by calling the

1 prescriber or otherwise, but didn't write it down?

2 A. I do not.

3 Q. Okay. I think I understood your answer  
4 last week, so I will only ask you once and not for  
5 all the flags.

6 But you didn't do any analysis or ask  
7 McCann to do any analysis to understand what the  
8 number of red flags would have changed away from  
9 16,700, if, for example, the distance was changed to  
10 30 miles?

11 A. Correct.

12 Q. Okay. Did you do any analysis or ask  
13 McCann to provide any analysis of how many of the  
14 total 305,000 prescriptions hit only on Flag 1?

15 A. I believe there's a chart that says how  
16 many were one flag, multiple flags.

17 But I know in the spreadsheets, I have  
18 that information. I did have how many prescriptions  
19 hit on Flags 1 through 14, in the information I  
20 reviewed.

21 Q. So let me make sure we're saying the same  
22 thing.

23 When I look at Page 111, I see how many  
24 flags -- I'm sorry -- I see how many prescriptions  
25 hit on each flag.

1 Q. Brice?

2 A. Yes.

3 Q. Is it your testimony that she was  
4 specifically asked about training materials about  
5 where to put notes, and she said she had never seen  
6 it before?

7 MR. ELSNER: Objection.

8 THE WITNESS: Not specific to notes, but  
9 if there was training documents and you  
10 reference, in those training documents, there  
11 was a portion about where to place the notes,  
12 then my reference is back to that training  
13 document.

14 BY MS. WHITE:

15 Q. If that exists in those documents?

16 MR. ELSNER: Objection.

17 (Whereupon, an off-the-record  
18 discussion was held.)

19 MS. WHITE: Oh, I said if that exists.

20 You can strike that.

21 BY MS. WHITE:

22 Q. I wanted to ask you about the electronic  
23 note system.

24 Are you familiar with EnterpriseRx, the  
25 system used at Publix?

1           A. I am not.

2           Q. Have you ever, in practicing pharmacy,  
3 yourself, used an electronic dispensing software?

4           A. No.

5           Q. What -- in -- not in practicing yourself,  
6 in any other respect, have you utilized or observed  
7 or been given a demonstration of electronic  
8 dispensing software?

9           A. Yes.

10           MR. ELSNER: Objection, form.

11 BY MS. WHITE:

12           Q. And what was the context in which that  
13 happened?

14           A. Various presentations or programs, where  
15 they would talk about what patient profile, what new  
16 systems would be like, the various pharmacy  
17 meetings, I received demonstrations of what the  
18 dispensing process would be, either PDX system or  
19 other proprietary systems, as part of our work at  
20 NABP.

21           Q. Was any -- so sorry.

22           Were any of the systems EnterpriseRx?

23           A. No.

24           Q. Do you have an opinion, generally, on  
25 whether the use of the EnterpriseRx system and the

Page 190

1 way that the notes are set up for input in that  
2 system meets the standard of care?

3 A. I'm not prepared to answer that.

4 Q. Okay. Do you have an opinion on a  
5 pharmacy electronic dispensing software that does,  
6 in your opinion, assist pharmacists in meeting the  
7 standard of care?

8 MR. ELSNER: Objection.

9 THE WITNESS: Is the question does an  
10 electronic system assist, or am I aware that  
11 any system that does assist?

12 BY MS. WHITE:

13 Q. Are you aware of a particular name of a  
14 product or system that you think assists pharmacists  
15 in making the kinds of notes that form your opinion?

16 A. What I'm aware of is that the systems  
17 should do that, but I'm not -- I can't identify any  
18 system that does.

19 Q. Okay. Let's move to talking a little bit  
20 more about the GDNA.

21 Now, we talked about them a little bit  
22 this morning, right?

23 A. Yes.

24 Q. And, in fact, I learned something new this  
25 morning, which is that you had -- between 2015 and I

Page 268

1 C E R T I F I C A T E


2 The within and foregoing deposition of the  
3 witness, CARMEN CATIZONE, MS, RPh, DPh, was taken  
4 before GREG S. WEILAND, CSR, RMR, CRR, at  
5 Suite 4400, One North Wacker Drive, in the City of  
6 Chicago, Cook County, Illinois, commencing at 8:33  
7 a.m., on the 30th day of May, 2024.

8 The said witness was first duly sworn and  
9 was then examined upon oral interrogatories; the  
10 questions and answers were taken down in shorthand  
11 by the undersigned, acting as stenographer; and the  
12 within and foregoing is a true, accurate and  
13 complete record of all the questions asked of and  
14 answers made by the aforementioned witness at the  
15 time and place hereinabove referred to.

16 The signature of the witness was not  
17 waived and the deposition was submitted to the  
18 deponent as per copy of the attached letter.

19 The undersigned is not interested in the  
20 within case, nor of kin or counsel to any of the  
21 parties.

22 Witness my signature on this 4th day of  
23 June, 2024.

24 

25 GREG S. WEILAND, CSR, RMR, CRR License No. 084-003472